(Q35144001)

6 August 2017

1 reference

title

Recent progress in tumour vaccine development (English)

1 reference

6 August 2017

3

W Martin Kast

1 reference

6 August 2017

I Caroline Le Poole

1

1 reference

6 August 2017

Hemamalini Bommiasamy

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

971-981

1 reference

Vaccine therapies for non-Hodgkin's lymphoma.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Analysis of the antibody repertoire of lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Getting peptide vaccines to work: just a matter of quality control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Peptide-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Toll-like receptors as adjuvant receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Immune complex-mediated antigen presentation induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Antitumor vaccination with HER-2-derived recombinant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34(+) cord blood-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

How to deal with polarized Th2 cells: exploring the Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Recent advances in multiple myeloma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Cytokine modified tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Intermediate- and high-risk melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.971

10.1517/13543784.12.6.971

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference